{
    "clinical_study": {
        "@rank": "67218", 
        "arm_group": {
            "arm_group_label": "Sarilumab SAR153191 (REGN88)", 
            "arm_group_type": "Experimental", 
            "description": "Single dose of simvastatin before and after sarilumab administration"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To evaluate the effect of a single 200 mg subcutaneous injection of sarilumab on the\n      pharmacokinetics of simvastatin in patients with rheumatoid arthritis\n\n      Secondary Objective:\n\n      To describe the safety and efficacy (exploratory) of sarilumab"
        }, 
        "brief_title": "Sarilumab Effect on the Pharmacokinetics of Simvastatin", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "The duration of the entire study per patient completing both Parts A and B is expected to be\n      approximately 58 weeks (not including Screening)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Male or female, between 18 and 75 years of age, inclusive. Body weight between 50.0 and\n        120.0 kg, inclusive, if male, and between 40.0 and 110.0 kg, inclusive, if female.\n\n        Diagnosis of RA, according to the ACR/European League against Rheumatism (EULAR) 2010\n        Rheumatoid Arthritis Classification Criteria with \u2265 3 months disease duration, ACR Class\n        I-III functional status, based on 1991 revised criteria (Appendix B, 5).\n        Moderate-to-severely active RA, defined as:\n\n          -  at least 4 of 68 tender joints and 4 of 66 swollen joints, and\n\n          -  high sensitivity C-reactive protein (hs-CRP) \u2265 8 mg/L On stable background RA\n             medication of methotrexate 10 to 25 mg/week, with folic/folinic acid to minimize\n             toxicity, for at least 12 consecutive weeks prior to inclusion.\n\n        Laboratory parameters within the normal range (or defined screening threshold for the\n        Investigator site), unless the Investigator considers an abnormality to be clinically\n        irrelevant for RA patients; however following lab values must be met:\n\n          -  Hemoglobin >8.5 g/dL\n\n          -  White blood cells >3000/mm3\n\n          -  Neutrophils >2000/mm3\n\n          -  Platelet count >150 000 cells/mm3\n\n        Exclusion criteria:\n\n        Prior or current significant concomitant illness(es) that, according to Investigator's\n        judgment, would adversely affect the patient's participation in the study.\n\n        Women of childbearing potential not protected by highly-effective contraceptive method(s)\n        of birth control (as defined in the informed consent form), and/or who are unwilling or\n        unable to be tested for pregnancy Participation in any clinical research study that\n        evaluated an investigational drug or therapy within 5 half-lives or 60 days of the\n        Screening, whichever is longer.\n\n        Active TB or a history of incompletely treated TB Positive QuantiFERON\u00ae-TB Gold test at\n        screening (regardless of prior treatment status) History of chronic infection or active\n        infection History of, or current, autoimmune or inflammatory systemic or localized joint\n        disease(s) other than RA A systemic hypersensitivity reaction, other than localized\n        injection site reaction, to any biologic drug.\n\n        History or presence of drug or alcohol abuse. Prior or current interstitial lung disease\n        diagnosed by high resolution computed tomography and/or lung biopsy with consistent\n        findings on pulmonary function tests and corroborating clinical findings.\n\n        Prior or current history of malignancy, including lymphoproliferative diseases, other than\n        adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell or basal\n        cell carcinoma of the skin, within 5 years prior to the screening visit.\n\n        Uncontrolled diabetes mellitus, defined as glycosylated hemoglobin (HbA1c) \u22659% at the\n        screening visit.\n\n        Current treatment with anti-TNF agents or other biologics Current treatment with\n        RA-directed biologic agents with non- TNF-\u03b1 antagonist Any contra-indications to\n        simvastatin, according to the applicable labeling Current treatment with a statin within\n        14 days before inclusion\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017639", 
            "org_study_id": "INT12684", 
            "secondary_id": "U1111-1140-5082"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sarilumab SAR153191 (REGN88)", 
                "description": "Pharmaceutical form:Prefilled syringe of  sarilumab solution Route of administration: Subcutaneous injection", 
                "intervention_name": "sarilumab SAR153191 (REGN88)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sarilumab SAR153191 (REGN88)", 
                "description": "Pharmaceutical form:Film-coated  20 mg Tablet Route of administration: oral", 
                "intervention_name": "simvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Simvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Investigational Site Number 840002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38305"
                    }, 
                    "name": "Investigational Site Number 840003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75235"
                    }, 
                    "name": "Investigational Site Number 840001"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assessment of PK parameters - area under curve from zero time until the last measurable concentration (AUClast) and AUC for simvastatin", 
            "safety_issue": "No", 
            "time_frame": "Day 1 of Period 1 and Day 8 of Period 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017639"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of PK parameters - maximum concentration (Cmax), time to maximum concentration (tmax), and terminal half-life associated with the terminal slope (t1/2z) for simvastatin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Period 1 and Day 8 of Period 2"
            }, 
            {
                "measure": "Assessment of PK parameters - Cmax, AUClast, AUC, tmax, t1/2z for simvastatin acid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Period 1 and Day 8 of Period 2"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 of Period 1 up to a maximum of 1 year (week 58)"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}